Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present VBI Vaccines, Inc. New (OTC: VBIV).

Full DD Report for VBIV

You must become a subscriber to view this report.


Recent News from (OTC: VBIV)

Wired News - VBI Vaccines Reports Positive Data from Final Phase-1 Study for Preventative CMV Vaccine
Stock Monitor: Adaptimmune Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 14, 2018 / If you want access to our free research report on VBI Vaccines Inc. (NASDAQ: VBIV ), all you need to do is sign up now by clicking the following link www.active-investors.com/regi...
Source: ACCESSWIRE IA
Date: May, 14 2018 07:20
VBI Vaccines (VBIV) CMV Vaccine VBI - 1501A Final Phase I Data - Slideshow
The following slide deck was published by VBI Vaccines in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 11 2018 13:34
VBI's CMV vaccine candidate shows positive effect in early-stage study; shares ahead 11% premarket
Thinly traded micro cap VBI Vaccines (NASDAQ: VBIV ) is up  11%  premarket on light volume on the heels of its announcement of encouraging results from a Phase 1 clinical trial assessing CMV candidate VBI-1501. More news on: VBI Vaccines, Healthcare stocks news, Stocks on the m...
Source: SeekingAlpha
Date: May, 10 2018 08:53
VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine
CMV neutralizing antibodies against fibroblast cell infection induced in 100% of subjects who received the highest dose Safe and well-tolerated at all doses with no safety signals observed Conference call and webcast today, Thursday, May 10, 2018, at 8:30 a.m. EDT CAMBRIDGE, Ma...
Source: GlobeNewswire
Date: May, 10 2018 07:30
VBI Vaccines misses by $0.03
VBI Vaccines (NASDAQ: VBIV ): Q1 EPS of -$0.19 misses by $0.03 . Revenue of $0.18M (+38.5% Y/Y) Press Release More news on: VBI Vaccines, Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 01 2018 08:21
VBI Vaccines Announces First Quarter 2018 Financial Results and Provides Corporate Update
-- Enrollment completed in PROTECT Phase 3 clinical study of Sci-B-Vac ® Hepatitis B Vaccine -- -- Key upcoming milestones in 2018 for lead eVLP vaccine candidates, VBI-1501 for prevention of Congenital Cytomegalovirus (CMV) and VBI-1901 for the treatment of glioblastoma (GBM) -...
Source: GlobeNewswire
Date: May, 01 2018 08:00
Blog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
Stock Monitor: KemPharm Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on VBI Vaccines Inc. (NASDAQ: VBIV ). If you want access to this report all you need to do is sign up now by clicking the following...
Source: ACCESSWIRE IA
Date: April, 23 2018 07:30
VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
More than 1,600 subjects enrolled in PROTECT study Topline data expected mid-2019 CAMBRIDGE, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”) today announced the completion of enrollment with the last patient receiving the first do...
Source: GlobeNewswire
Date: April, 19 2018 08:00
VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modification Low-dose study arm: enrollment complete Intermediate-dose study arm: enrollment commenced CAMBRIDGE, Mass., April 17, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. ...
Source: GlobeNewswire
Date: April, 17 2018 08:00
Institutional Top Ideas Series: DAFNA Capital Management
In the last entry of this recently rebooted series, we took a look at top ideas from Broadfin Capital (whose performance more than doubled that of the IBB during time frame we looked at). Going forward, I hope to continue delve into the portfolios of successful hedge funds predominantly ...
Source: SeekingAlpha
Date: April, 13 2018 01:03

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-141.811.982.08161.81201,557
2018-08-131.921.821.941.78274,341
2018-08-102.031.912.131.8994,833
2018-08-091.942.032.181.92303,493
2018-08-081.941.8751.971.85332,129

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report. Get a complete short report on VBIV.


About VBI Vaccines, Inc. New (OTC: VBIV)

Logo for VBI Vaccines, Inc. New (OTC: VBIV)

Not available

 

Contact Information

 

 

Current Share Structure

     


    Recent Filings from (OTC: VBIV)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 10 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 01 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 01 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 20 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 17 2018
    Additional proxy soliciting materials - definitive
    Filing Type: DEFA14AFiling Source: edgar
    Filing Date: April, 16 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 10 2018
    Additional proxy soliciting materials - definitive
    Filing Type: DEFA14AFiling Source: edgar
    Filing Date: April, 10 2018
    Preliminary proxy statement providing notification matters to be brought to a vote
    Filing Type: PRE 14AFiling Source: edgar
    Filing Date: March, 29 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 14 2018

     

     


    Daily Technical Chart for (OTC: VBIV)

    Daily Technical Chart for (OTC: VBIV)


    Stay tuned for daily updates and more on (OTC: VBIV)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: VBIV)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VBIV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of VBIV and does not buy, sell, or trade any shares of VBIV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/